CentraCare Health

DigitalCommons@CentraCare Health
Articles

Posters and Scholarly Works

7-2015

Hematoma Enlargement Among Patients with
Traumatic Brain Injury: Analysis of a Prospective
Multicenter Clinical Trial
M Fareed K. Suri
CentraCare Health, surim@centracare.com

Adnan I. Qureshi
CentraCare Health, qureshia@centracare.com

Ahmed A. Malik
Malik M. Adil
Archie Defillo
See next page for additional authors

Follow this and additional works at: https://digitalcommons.centracare.com/articles
Part of the Neurology Commons
Recommended Citation
Qureshi, A. I., Malik, A. A., Adil, M. M., Defillo, A., Sherr, G. T., & Suri, M. F. K. (2015). Hematoma Enlargement Among Patients
with Traumatic Brain Injury: Analysis of a Prospective Multicenter Clinical Trial. Journal of vascular and interventional neurology,
8(3), 42.

This Article is brought to you for free and open access by the Posters and Scholarly Works at DigitalCommons@CentraCare Health. It has been
accepted for inclusion in Articles by an authorized administrator of DigitalCommons@CentraCare Health. For more information, please contact
schlepers@centracare.com.

Authors

M Fareed K. Suri, Adnan I. Qureshi, Ahmed A. Malik, Malik M. Adil, Archie Defillo, and Gregory T. Sherr

This article is available at DigitalCommons@CentraCare Health: https://digitalcommons.centracare.com/articles/31

Hematoma Enlargement Among Patients with Traumatic Brain Injury:
Analysis of a Prospective Multicenter Clinical Trial
1

1

1

2

Adnan I. Qureshi, MD , Ahmed A. Malik, MD , Malik M. Adil, MD , Archie Defillo, MD , Gregory
2
2
T. Sherr, MD , and M. Fareed K. Suri, MD
1Zeenat

Qureshi Stroke Institute, 519 2nd St N, St Cloud, MN 56303, USA

2CentraCare

Health System, 1406 6th Ave N, St Cloud, MN 56303, USA

Abstract
Journal of Vascular and Interventional Neurology, Vol. 8

Observational studies suggest that hematomas continue to enlarge during hospitalization in patients with
traumatic brain injury (TBI). There is limited data regarding factors associated with hematoma enlargement
and on whether hematoma enlargement contributes directly to death and disability in patients with TBI.
We analyzed data collected as part of the Resuscitation Outcomes Consortium Hypertonic Saline and TBI
Study. Hematoma enlargement was ascertained and collected as a predefined safety endpoint. We evaluated
the effect of hematoma enlargement on the risk of death and disability at 6 months based on the Extended
Glasgow Outcome Scale (GOSE) (dichotomized as >4 or ≤4) using stepwise logistic regression analysis.
We adjusted for age (continuous variable), admission GCS score (dichotomized at >5 and ≤5), and computed tomography (CT) scan classification (Marshall grades entered as a categorical variable).
Of the 1200 patients with severe TBI analyzed, 238 (19.8%) patients were reported to have hematoma
enlargement as an adverse event. The proportion of patients who reached favorable outcome at 6 months
was significantly lower (defined by GOSE of >4) among patients with hematoma enlargement (29.0% vs.
40.1%, p<.0001). The proportion of patients who died within 6 months was significantly higher among
patients with hematoma enlargement (31.9% vs. 20.7%, p<.0001). After adjusting for age, admission GCS
score, and initial injury score, the odds of favorable outcome was lower in patients with hematoma enlargement (odds ratio 0.7, 95% confidence interval [CI]; 0.5–0.97).
Our results suggest that hematoma enlargement may be a direct contributor to death and disability in
patients with TBI at 6 months. Future clinical trials must continue to evaluate new therapeutic interventions
aimed at reducing hematoma enlargement with a favorable risk benefit ratio in patients with TBI.
Keywords
traumatic brain injury; hematoma enlargement; extended Glasgow Outcome Scale; hypertonic saline; mortality

Background
Observational studies have suggested that intracranial
hemorrhage continues to enlarge in almost 30–42% of
patients with traumatic brain injury (TBI) [1–3]. The
risk of hematoma enlargement is higher in patients who
are studied early after occurrence of TBI [3]. In an
observational study, hematoma enlargement was
observed in 51% of the 63 patients with initial computed

tomography (CT) scan performed within 4 hours of TBI
[4]. Identification of factors associated with, or predictive of, hematoma enlargement in patients with TBI may
be important to identify a group of patients who are high
risk, and in whom the risk benefit ratio of new therapeutic strategies may be acceptable. Hematoma enlargement
appears to be associated with a high rate of neurological
deterioration in patients with TBI [5,6]. In a study of
171 patients, 54 (32%) suffered progressive brain injury
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due to enlargement of intracranial hemorrhages [7].
However, previous studies have been unable to conclusively determine whether hematoma enlargement contributes directly to death and disability or is a manifestation of severe TBI[3,7] and thus not an appropriate therapeutic target.
We performed this study to address some of the aforementioned issues regarding hematoma enlargement in a
prospectively studied cohort of patients with TBI.

Methods
Journal of Vascular and Interventional Neurology, Vol. 8

We analyzed data collected as part of the Resuscitation
Outcomes Consortium Hypertonic Saline (ROC HS)
Trial Shock Study and Traumatic Brain Injury (TBI)
Study. The details regarding the trial have been published previously [8]. Briefly, a multicenter, doubleblind, randomized, placebo-controlled clinical trial
involving 114 North American emergency medical services agencies, within the ROC, was conducted between
May 2006 and May 2009. The study sought to determine
whether prehospital administration of 7.5% hypertonic
saline/dextran, compared to current standard therapy
with normal saline, as an initial resuscitation fluid,
affects survival following traumatic injury with hypovolemic shock or severe TBI as manifested by a prehospital Glasgow coma score (GCS) of 8 or less. The study
was terminated by the data and safety monitoring board
after randomization of 1331 patients, having met prespecified futility criteria. We included the TBI cohort in our
analysis, which included patients with blunt trauma, prehospital GCS score ≤ 8, and age ≥15 years or weight
≥50kg. Patients with TBI, who met the criteria for hypovolemic shock, were included in the shock cohort.
Patients were randomized to a single dose 7.5% saline in
6% Dextran-70 (250cc), 7.5% saline (no dextran)
(250cc), or crystalloid (250cc) as the initial fluid for prehospital resuscitation. In an effort to minimize variability in the subsequent care of trauma patients, all sites
agreed to encourage the implementation of resuscitation
and critical care management guidelines, which included
clinical protocol for trauma resuscitation, transfusion
guidelines, intensive care unit (ICU) insulin infusion/
blood glucose control, sedation/analgesia protocol for
mechanical ventilation, mechanical ventilation protocol,
venous thromboembolism prophylaxis, protocol for ventilator associated pneumonia, and management of severe
TBI.
This initial data, including demographics, mechanism of
injury, prehospital and emergency department (ED)
hemodynamic variables, time to definitive care, mode of
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transport, injury severity score (ISS), the presence of
TBI, and total fluids in the first 12 hours were collected
prospectively as patient care progressed. Data collection
was based on a daily review of the medical records and
results of diagnostic studies. All in-hospital electrolyte
levels in the first 24 hours were tracked. Information
regarding the initial resuscitation of the patient, intracranial pressure (ICP) monitoring and management, neurologic assessment based on the GCS, and adherence to
the clinical care guidelines was collected. Serum sodium
values upon admission and every 8 hours for the first 24
hours were collected for all patients requiring ICU
admission. Any sodium value >160 mEq/L requiring
therapeutic intervention, any seizure activity associated
with hypernatremia, and any sodium values >
160 mEq/L without intervention, were considered serious adverse events. Total fluid and blood products
required in the first 24 hours and coagulation parameters
on admission were recorded for all patients. For patients
with TBI, the results of the first three head CT scans
obtained within the first week after injury were collected. ICP and cerebral perfusion pressure (CPP) at the
time of ICP monitor placement, total hours of ICP
>25 mmHg and CPP <60 mmHg (measured in increments of 15 minutes), and total amount of mannitol
administered in 12-hour period of time for the first 48
hours after injury were also collected. The time interval
between TBI onset and CT scan was estimated as the
sum of time intervals between 911 call and ED admission and between ED admission and CT scan.
Certain adverse events were collected as safety endpoints, which included evidence of increased intracranial
hemorrhage on head CT scan. All members of the
trauma team were instructed as to recognize the possible
adverse events prior to initiation of the trial and were
instructed to immediately report any suspected adverse
event to the investigators using an emergency contact
number. Any expeditable serious and life-threatening
adverse event was reported to the Food and Drug
Administration (FDA), Institutional Review Board
(IRB), and chairperson of the Data Monitoring Committee (DMC) within 72 hours by telephone, and by a written report, submitted within 7 days. All nonlife-threatening unexpected serious adverse events were reported in
writing within 15 days. The main outcome measure was
six-month neurologic outcome based on the Extended
Glasgow Outcome Scale (GOSE) (dichotomized as >4
or ≤4) obtained by telephone survey. Additional neurological outcomes included disability rating score (DRS)
(at discharge and 6 months), and 28-day and 6-month
survival.
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We performed all analyses using the IBM SPSS 20 statistical software (IBM Corp., Armonk, NY). Means and
frequencies were compared using one-way analysis of
variance and the [chi] [2] method, respectively. We evaluated the association of hematoma enlargement with the
patients’ demographic and clinical and laboratory characteristics. Baseline variables of interest included age,
race, gender, initial systolic blood pressure (BP), admission GCS, baseline hemoglobin level, platelet count,
fibrinogen levels, and sodium levels. These variables
were dichotomized based on either median values (e.g.,
GCS score, serum sodium) or normal ranges (e.g., baseline hemoglobin) to identify clinically meaningful cutoff
values for defining association.

Journal of Vascular and Interventional Neurology, Vol. 8

We evaluated the effect of hematoma enlargement on the
risk of death and disability at 6 months based on GOSE
(dichotomized as >4 or ≤4) [9] using stepwise logistic
regression analysis. We adjusted for age (continuous
variable), admission GCS score (dichotomized at >5 and
≤5), and CT scan classification (Marshall grades II, III,
and mass lesion entered as a categorical variable) [10–
12]. Because our study cohort also included polytrauma
patients, we adjusted for ISS (dichotomized at >26 and
≤26) in the model [13–15]. A second multivariate analysis was performed using death within 6 months as the
dependent variable and the model was adjusted for the
same potential confounding factors as mentioned above.
A p value below 0.05 was defined as an entry criterion
in each of the stepwise regressions. A p value below
0.05 was considered significant.

Results
Of the total of 1224 patients with severe TBI recruited in
the trials, 1200 were analyzed. Patients who died en
route (n = 4) and those who died on arrival to the ED (n
= 54) were excluded. The mean age (± standard deviation [SD]) of the study cohort was 39±18 years and the
median GCS score was 3 (range 3). There were 238
(19.8%) patients who were reported to have hematoma
enlargement as an adverse event. The mean (95% confidence interval [CI]) estimated time interval between TBI
onset and CT scan was 114 minutes (95% CI: 100–127)
and 130 minutes (95% CI: 116–144) in patients with and
without hematoma enlargement (p value = 0.26), respectively.
The mean age (±SD) of patients who had hematoma
enlargement was similar in patients who underwent
hematoma enlargement compared with those who did
not have enlargement (39±17 vs. 39±18 years, p = 0.9).
There were no differences between the two groups in

Figure 1. The proportion of surviving patients with Glas-

gow Coma Scale (Gcs) score of ≤5 in severe Tbi patients
with and without hematoma expansion expressed on a
daily basis.

regards to gender and race/ethnicity. The mean initial
systolic BP was higher in patients with hematoma
enlargement than those without hematoma enlargement
(146±30 vs. 140±30, p = 0.01). The proportion of
patients with admission GCS score ≤5 was higher
among patients who underwent hematoma enlargement.
The ISS was significantly higher among those who
underwent hematoma enlargement. The proportion of
patients with ISS score >26 was significantly higher
among those with hematoma enlargement. There was a
trend for mean fibrinogen levels to be lower among
those who underwent hematoma enlargement. There was
no difference in proportion of patients randomized to
hypertonic saline with or without dextran in patients
who had hematoma enlargement compared with those
who did not have hematoma enlargement. The proportion of patients with diffuse injury types II and III, and
mass lesions on initial CT scans were higher among
patients who underwent hematoma enlargement.
The proportion of patients with best GCS ≤5 continued
to be higher among patients with hematoma enlargement
on Days 2 through 5 (Fig. 1). The requirements for ICP
monitoring, ventriculostomy, and craniotomy were
higher among patients with hematoma enlargement,
which was evident within the first 12 hours. The hours
of time spent with ICP>25 mm Hg, CPP<60 mmHg, and
the proportion of patients with serum sodium
>145 mmol/L within the first 12 hours was not different
between patients who underwent hematoma enlargement
compared with those who did not have enlargement. The
mean amount of mannitol used (g/kg) in the first 12
hours was higher among those who underwent hematoma enlargement. A significantly higher proportion of
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Table 1. The association of hematoma enlargement with the patients’ demographic, and clinical and laboratory characteristics in patients with severe Tbi

Journal of Vascular and Interventional Neurology, Vol. 8

Overall number (%)
Age, mean±SD
Gender
Men
Women
Race/ethnicity
Asian
African American
White
Other
Hispanic or Latino
Randomization group
Hypertonic saline/dextran
Hypertonic saline
Normal saline
Out-of-hospital GCS (median, range)
Out-of-hospital GCS >5
Out-of-hospital GCS ≤5
ISS, (median, range)
ISS >26
ISS ≤26
Marshall Score, first head CT scan
Diffuse injury I
Diffuse injury II
Diffuse injury III
Diffuse injury IV
Mass lesion
Others
Out-of-hospital advanced airway
Time from dispatch call to fluid administration, min (mean±SD)
Total out-of-hospital time, min (mean±SD)
Out-of-hospital fluids, L (mean±SD)

Patients without hematoma
enlargement
962
39±18

Patients with hematoma enlargement
238
39±17

738(76.7)
224(23.3)

176(73.9)
62(26.1)

0.4

27(2.8)
93(9.7)
489(50.8)
12(1.2)
19 (2.0)

9(3.8)
12 (5.0)
114(47.9)
3(1.3)
7(2.9)

0.2

279(29.0)
260(27.0)
423(44.0)
5±2
421(43.8)
399(41.5)
24±16
368(38.3)
575(59.8)

56(23.5)
60(25.2)
122(51.3)
4±2
11(4.6)
149(62.6)
33±12
151(63.4)
85(35.7)

366(38.0)
319(33.2)
101(10.5)
31(3.2)
132(13.7)
12(1.2)
573(59.6)
35.0±23.6
57.1±29.4
0.8±0.6

6(2.5)
114(47.9)
44(18.5)
12(5.0)
59(24.8)
3(1.3)
151(63.4)
34.7±22.5
54.8±27.3
0.8+0.7

p-value
0.9

0.1
0.4
0.08
<.0001
<.0001

<0.0001
0.3
0.9
0.3
0.7

Abbreviations: CT, computed tomography; GCS, Glasgow Coma Score; ISS, Injury Severity Score; L, liters; min, minutes; Range for GCS, 3 through 15;
range for ISS, 0 through 75; SD, Standard deviation

patients required mannitol, additional hypertonic saline,
and hyperventilation within the first 5 days among
patients who underwent hematoma enlargement. The
amount of fresh frozen plasma, cryoprecipitate, and platelets transfused were higher among patients who underwent hematoma enlargement. There were significantly
higher rates of in-hospital adverse events, including
pneumonias, urinary tract infections, and overall nosocomial infections, in patients who underwent hematoma
enlargement. The total ICU days and hospital days were
significantly higher, and ventilator free days were significantly lower among patients with hematoma enlargement.
The proportions of patients in DRS categories of moderately severe/severe/extremely severe or vegetative/
extreme vegetative/dead were significantly higher
among patients with hematoma enlargement compared
with those without enlargement at both 1 month and 6
months. The proportion of patients who reached favorable outcome at 6 months was significantly lower
(defined by GOSE of >4) among patients with hematoma enlargement (29.0% vs. 40.1%, p <.0001). The
proportion of patients who died within 6 months was
significantly higher among patients with hematoma

enlargement (31.9% vs. 20.7%, p<.0001). After adjusting for age, admission GCS score, and initial trauma
score, the odds of favorable outcome was lower in
patients with hematoma enlargement (odds ratio [OR]
0.7, 95% CI; 0.5–0.97). After adjusting for age, admission GCS score, and initial trauma score, the odds of 6
month survival was not significantly lower in patients
with hematoma enlargement (OR 0.9, 95% CI; 0.6–1.2).

Discussion
In our cohort of severe patients with TBI, hematoma
enlargement was observed in 20% of the patients who
survived prehospital resuscitation. The proportions of
patients in DRS categories of severe, vegetative and
dead were significantly higher among patients with hematoma enlargement at both 1 month and 6 months. The
rate of favorable outcomes and survival at 6 months was
significantly lower among patients who underwent hematoma enlargement. It is possible that hematoma
enlargement was a manifestation of severe TBI and
higher rates of death and disability are related to severity
of initial TBI. In such circumstances, preventing, or
ameliorating, hematoma enlargement is unlikely to
reduce the death and disability associated with TBI. We
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Table 2. The association of hematoma enlargement with in-hospital physiological parameters, therapeutic
interventions, and adverse events in patients with severe TBI.
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Overall number (%)
Admission physiology
Admission systolic blood pressure, mmHg (mean±SD)
Admission systolic blood pressure ≤140 mmHg
Admission systolic blood pressure >140 mmHg
Admission systolic blood pressure ≤90 mmHg
Admission GCS (median, range)
Admission GCS >5
Admission GCS ≤5
Hemoglobin g/dL (mean±SD)
Admission INR (mean±SD)
Admission serum sodium, mEq/L (mean±SD)
Serum sodium >145 mEq/L
At 0–4 h
At 4–12 h
At 12–24 h
First ED platelet count (mean±SD)
First ED fibrinogen level, mg/dL (mean±SD)
Neurologic monitoring
ICP monitored
Initial ICP, mmHg (mean±SD)
Initial ICP ≥25 mmHg
Initial ICP <25 mmHg
Highest ICP in the first 12h, mmHg (mean±SD)
Highest ICP ≥25 mmHg in first 12 h
Highest ICP <25 mmHg in first 12 h
Hours with ICP >25 mmHg in the first 12 h (mean±SD)
Initial CPP, mmHg (mean ± SD)
Initial CPP ≥60 mmHg
Initial CPP <60 mmHg
Hours with CPP <60 mmHg in first 12h (mean±SD)
Interventions for intracranial hypertension
Total mannitol in first 12 h, g/kg (mean(95%CI))
Mannitol in first 5 d
Additional hypertonic fluids in first 5d
Hyperventilation
First 24 h
First 5 d
Ventriculostomy
First 24 h
First 5 d
Craniotomy
First 24 h
First 5 d
In hospital management
Intubated in ED
FFP (mL) given (mean(95%CI))
Cryoprecipitate (mL) given (mean(95%CI))
Platelets (mL) given (mean(95%CI))
Total Fluids in First 24hrs, L (mean±SD)
Adverse events
≥1 Nosocomial infections
Pneumonia
Bloodstream infection
Urinary tract infection
Wound infection
Hypernatremia (sodium >160 mEq/L) requiring intervention
Seizures in first 24 h

Patients without hematoma enlargement
Patients with hematoma enlargement P-value
962
238
140 ± 30
499(51.9)
463(48.1)
49(5.1)
3±4
334(34.7)
625(65.0)
12.8 ± 2.2
1.2 ± 0.5
143 ± 5.8

146 ± 30
106(44.5)
132(55.5)
9(3.8)
3±3
61(25.6)
177(74.4)
12.6 ± 2.2
1.2 ± 0.4
142 ± 6.1

0.01

361(37.5)
222(23.1)
173(18.0)
237660 ± 72316
227.4 ± 102.6

82(34.5)
76(31.9)
72(30.3)
236770 ± 70542
205.5 ± 72.8

0.3
0.1
0.01
0.9
0.06

207(21.5)
16±15
32(3.3)
152(15.8)
23±19
64(6.7)
139(14.4)
0.9 ± 2.6
73.9 ± 22.3
142(14.8)
35(3.6)
1.6 ± 3.0

146(61.3)
19±14
31(13.0)
97(40.8)
27±18
63(26.5)
82(34.5)
1.3 ± 2.8
72.2 ± 20.3
82(34.5)
28(11.8)
1.8 ± 3.1

<.0001
0.1

5.5(2.4–8.6)
152(15.8)
82(8.5)

12.4(7.5–17.4)
99(41.6)
54(23.9)

0.01
<.0001
<.0001

10(1.0)
15(1.6)

13(5.5)
13(5.5)

<.0001
<.0001

75(7.8)
80(8.3)

73(30.7)
80(33.6)

<.0001
<.0001

83(8.6)
88(9.1)

71(29.8)
79(33.2)

<.0001
<.0001

280(29.1)
217.7(177.8-257.6)
8.0 (5.0-11.0)
39.9(27.0-52.7)
6.5±5.4

91(38.2)
416.0 (295.7-536.4)
18.2(7.4-29.0)
96.9(58.0-135.7)
8.2±5.7

0.006
<.0001
0.01
0.001
<.0001

235(24.4)
168(17.5)
44(4.6)
66(6.9)
19(2.0)
25(2.6)
18(1.9)

101(42.4)
73(30.7)
19(8.0)
27(11.3)
13(5.5)
12(5.0)
1(0.4)

<.0001
<.0001
0.05
0.04
0.005
0.05
0.1

0.04
0.4
0.002
0.007
0.4
0.6
0.05

0.1
0.05
0.02
0.1
0.5
0.3
0.5

Abbreviations: CI, confidence interval; CPP, cerebral perfusion pressure; d, days; ED, emergency department; FFP, fresh frozen plasma; GCS, Glasgow
Coma Score; h, hours; ICP, intracranial pressure; INR, International normalization ratio; SD, standard deviation

performed multivariate analysis to adjust for known predictors, such as age, admission GCS score, admission
ISS, and CT scan findings. Hematoma enlargement
reduced the odds of favorable outcomes at 6 months,
independent of the known predictors of 6-month outcome in patients with TBI. Therefore, it appears that
hematoma enlargement directly contributes to death and

disability among patients with TBI. Our ability to conclusively demonstrate the relationship between hematoma enlargement and 6-month outcome is related to the
large sample size and high compliance with the 6-month
follow-up assessment. Previous smaller studies have
supported our conclusions. Oertel et al.,[3] in a study of
142 patients with TBI, reported that 17% of patients
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Table 3. The association of hematoma enlargement with outcome measures in patients with severe TBI.
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Overall number (%)
Outcome
6-month GOSE ≤4
6-month GOSE >4
DRS categories of disability - 1 month
0–1 (none/mild)
2–6 (partial/moderate)
7–21(moderately severe/severe/extremely severe)
22–30 (vegetative/extreme vegetative/dead)
DRS categories of disability - 6 month
0–1 (none/mild)
2–6 (partial/moderate)
7–21 (moderately severe/severe/extremely severe)
22–30 (vegetative/extreme vegetative/dead)
28-day survival
6 month survival
Ventilator-free days, (mean±SD)
Total ICU days, (mean±SD)
Total hospital days, (mean±SD)

Patients without hematoma enlargement Patients with hematoma enlargement P-value
962
238
410(42.6)
386(40.1)

147(61.8)
69(29.0)

<.0001

109(11.3)
172(17.9)
41(4.3)
199(20.7)

16 (6.7)
50(21.0)
13(5.5)
75(31.5)

0.02

304(31.6)
221(23.0)
63(6.5)
206(21.4)
779(81.0)
763(79.3)
19.4 ± 11.1
7 ± 13
16 ± 25

47(19.7)
67(28.2)
24(10.1)
78(32.8)
172(72.3)
162(68.1)
14.1 ± 10.6
11 ± 10
26 ± 27

<.0001
0.002
<.0001
<.0001
<.0001
<.0001

Abbreviations:; DRS, Disability Rating Score; GOSE, Extended Glasgow Outcome Score; ICU, intensive care unit; SD, standard deviation

with hematoma enlargement and 28% of patients without hematoma enlargement had a favorable neurological
outcome at discharge (p = 0.13). Six-month follow-up
data were obtained in only 51% of patients. At 6
months, a favorable neurological outcome was seen in
60% of patients with hematoma enlargement and in 70%
of those without hematoma enlargement, respectively (p
= 0.34). Narayan et al.,[4] in a study of 64 patients,
reported that 7 of 35 (20%) TBI patients with hematoma
expansion and 1 of 25 (4%) TBI patients without hematoma expansion died.
The most likely explanation is that the higher death and
disability was due to secondary neurological injury
among those who underwent hematoma enlargement.
The proportion of patients with GCS score ≤5 remained
greater over each successive day, postadmission, among
those with hematoma enlargement. The requirement for
mannitol, additional hypertonic saline, and hyperventilation was higher within the first 5 days among patients
who underwent hematoma enlargement. Such observations suggest a higher rate of secondary neurological
injury among those who underwent hematoma enlargement. The higher proportion of in-hospital adverse
events such as nosocomial infections may have contributed to increasing the rate of death and disability among
patients with hematoma enlargement. Our observations
are similar to the study by Oertel et al.,[3] which reported that the proportion of patients with mean daily ICP >
20 mmHg was higher in those with hematoma enlargement compared with those without hematoma enlargement. Previous investigators also reported that patients
who undergo hematoma enlargement have larger hemorrhages and a higher frequency of subdural hemorrhages
and/or subarachnoid hemorrhages on initial CT scan
[4,16]. This may further predispose such patients to the

exaggerated detrimental effect of increase in intracranial
mass effect, due to limited intracranial compliance.
Previous studies have not been able to identify consistent predictors of hematoma enlargement [2]. Patients
who undergo early CT scan after TBI are more likely to
undergo hematoma enlargement [1,3,4,7], although
some studies including ours have not confirmed this
observation [2]. We observed that GCS ≤5 and ISS ≤26,
at admission, were associated with a higher rate of hematoma enlargement. The relationship between lower
GCS and hematoma enlargement in patients with TBI
was also identified by Chieregato et al [16]. Large size
intraparenchymal hemorrhages, subdural hemorrhages,
and/or subarachnoid hemorrhages on initial CT scan
appear to be associated with a higher risk of hematoma
enlargement [4,16]. We observed that the pattern of
injury on initial CT scan (categorized by the Marshall
classification) was associated with a risk of hematoma
enlargement similar to a previous study [16]. Elevated
international normalized ratio (INR) or D-dimer concentrations were associated with hematoma enlargement
[7]. Similar to our study, other studies have not been
able to demonstrate any relationship between laboratory
measures of coagulopathy and hematoma enlargement
[2]. However, patients who underwent hematoma
enlargement in our study were more likely to receive
fresh frozen plasma, cryoprecipitate, and platelet transfusions presumably to prevent further enlargement once
CT scan evidence of hematoma enlargement was detected. Furthermore, we wanted to study the effect of
hypertonic saline, which has become a commonly used
agent in the treatment of severe TBI, [17–20] on hematoma enlargement. Hypertonic saline decreases platelet
function, impairs the integrity of the plasma coagulation
system, [21,22] and may increase the rate of hematoma
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enlargement in patients with TBI. We did not observe
any evidence to support that hypertonic saline bolus
increases the risk of hematoma enlargement.
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Our analysis has certain limitations that should be considered. The protocol for acquisition of serial CT scans
was not specified and variation can be expected within
institutions. Most likely, patients underwent CT scans
subsequent to a neurological deterioration. Changes in
serial CT scans may be detected in the absence of neurological deterioration [23]. However, previous studies
have not found any abnormalities on serial CT scans, in
the absence of neurological deterioration, that result in
therapeutic decisionmaking [24,25]. Therefore, the rate
of hematoma enlargement maybe underestimated in our
analysis. Most of such undetected enlargements, however, are probably asymptomatic and do not require any
therapeutic interventions. We did not use blinded or central interpretation of CT scans to identify hematoma
enlargement and the ascertainment of hematoma
enlargement was made by study investigators. Therefore, interobserver variation can be expected in identification of hematoma enlargement. The rates of hematoma enlargement have been higher in studies that use
quantitative central analysis of CT scans in patients with
TBI [4]. While each site in the trial was encouraged to
implement resuscitation and critical care management
guidelines, previous studies have found variance
between institutions in compliance to such guidelines
[26]. The effect of such variations on our results is undetermined, although a differential compliance based on
presence or absence of hematoma enlargement is
unlikely.
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